Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
National plan sits at the center of this dementia and brain health question.
The National Plan to Address Alzheimer’s Disease is undergoing a comprehensive update scheduled for release in late 2026, marking the first major revision since the previous plan cycle. The update process began in early 2026 with an Advisory Council meeting on February 9, 2026, and represents a significant evolution driven by breakthrough drug approvals, an expanding clinical trial pipeline with 138 drugs currently in 182 clinical trials, and the October 2024 reauthorization of the National Alzheimer’s Project Act (NAPA) that extends federal coordination through 2035. The 2026 update will fundamentally reshape how the nation approaches Alzheimer’s prevention, treatment, and care by incorporating public input through listening sessions, advice from an expanded Advisory Council that now includes people actually living with dementia, and alignment with current HHS priorities.
The timing of this update is critical because the field has changed dramatically. For example, the FDA approval of Leqembi’s once-weekly injectable form (LEQEMBI IQLIK™) on August 29, 2025, followed by an expected decision in May 2026 on starter doses for at-home self-administration, represents the kind of treatment advancement the original plan never anticipated. The National Plan serves as the federal government’s roadmap for coordinating Alzheimer’s and dementia research, care, prevention, and support across multiple agencies, and the 2026 revision will reflect these clinical gains while identifying remaining gaps.
Table of Contents
- What Is the National Plan to Address Alzheimer’s Disease and How Is It Being Updated?
- The 2026 Plan Development Process and Key Features
- Breakthrough Treatments and FDA Approvals Driving the 2026 Changes
- What New Treatment Options Are Coming in 2026?
- How the Expanded National Plan Addresses Care and Support Gaps
- Understanding the Implementation Timeline and Real-World Access
- What This Means for Alzheimer’s Care in the Coming Years
- Conclusion
What Is the National Plan to Address Alzheimer’s Disease and How Is It Being Updated?
The National Plan to Address Alzheimer’s Disease is a comprehensive federal strategy developed under the National Alzheimer’s Project Act (NAPA), which was originally signed into law in 2011. It coordinates efforts across the Department of Health and Human Services and other federal agencies to accelerate research, improve care quality, reduce disparity, and provide support for people with Alzheimer’s disease and their caregivers. The plan has historically set five-year goals and identified priority areas where federal investment and coordination could have the greatest impact on the nation’s response to Alzheimer’s. The 2026 update differs from previous revisions by incorporating a more inclusive and dynamic development process.
Instead of a traditional top-down planning effort, the current approach includes public engagement through requests for information, listening sessions where patients and caregivers can directly shape priorities, and expanded Advisory Council membership. The inclusion of people living with dementia on the Advisory Council represents a significant shift—previous plans were developed primarily by researchers, clinicians, and government officials, but the 2026 version will incorporate the lived experience of those most affected by the disease. The October 2024 NAPA Reauthorization Act, signed into law, extended the planning authority through 2035 and expanded the council to include representatives from additional federal agencies and community stakeholders. This reauthorization provides the legal framework and resources necessary to complete the 2026-2035 National Plan and ensures that federal coordination remains aligned with emerging scientific evidence and treatment options that didn’t exist just a few years ago.
The 2026 Plan Development Process and Key Features
The development process for the 2026-2035 National Plan began in earnest in early 2026, with an initial Advisory Council meeting on February 9, 2026, setting the direction for the comprehensive review. Over the coming months, HHS will conduct multiple listening sessions to gather input from patients, family caregivers, healthcare providers, researchers, and advocacy organizations. This collaborative approach ensures that the final plan reflects not just scientific priorities but also the practical realities of living with and treating Alzheimer’s disease. one important limitation of this timeline is that the plan won’t be finalized until late 2026, which means that federal resources and research priorities may remain somewhat in flux during this critical year.
For example, treatments like AXS-05 (designed to address agitation, which affects up to 76% of Alzheimer’s patients) have a FDA decision date of April 30, 2026, but the National Plan won’t incorporate lessons learned from its potential approval until months later. The plan’s development process, while more inclusive than previous efforts, also requires careful coordination across multiple federal agencies with different budgets and timelines. A key feature of the expanded plan will be how it addresses the growing complexity of Alzheimer’s research and treatment. With 138 drugs currently in 182 clinical trials, the field has moved far beyond the limited options available even five years ago. The 2026 plan will need to address how the federal government coordinates the approval, funding, and implementation of these diverse treatments while ensuring equitable access across different populations and geographic areas.
Breakthrough Treatments and FDA Approvals Driving the 2026 Changes
The most significant driver of the 2026 National Plan update is the approval of disease-modifying treatments that slow cognitive decline in early-stage Alzheimer’s disease. Leqembi (lecanemab) was the first anti-amyloid monoclonal antibody to receive FDA approval, followed by Kisunla (donanemab). These treatments represent a fundamental shift in Alzheimer’s care from symptom management to disease modification—addressing the underlying pathology of the disease rather than just treating its symptoms. The FDA approval of Leqembi’s once-weekly injectable form on August 29, 2025, and the scheduled May 2026 decision on starter doses for at-home self-administration represents another transformative moment. Previously, Leqembi required intravenous infusions in clinical settings, limiting access and requiring significant time commitments from patients and caregivers.
Home-based self-injection would dramatically expand access and improve quality of life for eligible patients. However, a significant warning here is that these treatments are only appropriate for people in the early stages of cognitive decline with documented amyloid pathology—they are not a cure and do not work for everyone. Additionally, amyloid-related imaging abnormalities (ARIA), including brain microhemorrhages and amyloid-related microinfarcts, remain important safety considerations that the 2026 plan will need to address in terms of monitoring and patient selection. The expanding pipeline of 138 drugs in 182 clinical trials suggests that the coming years will bring additional options targeting different aspects of Alzheimer’s pathology. Some target tau tangles, others address inflammation or blood-brain barrier dysfunction. The 2026 National Plan will need to establish frameworks for how these diverse treatment approaches should be prioritized, funded, and implemented within the healthcare system.
What New Treatment Options Are Coming in 2026?
Beyond the injectable Leqembi formulation, several important treatment decisions are expected in 2026. AXS-05 has a Prescription Drug User Fee Act (PDUFA) date of April 30, 2026, and addresses one of the most challenging behavioral aspects of Alzheimer’s disease—agitation. Clinical data shows that up to 76% of Alzheimer’s patients experience agitation at some point, often leading to caregiver burnout, increased care costs, and sometimes forced institutionalization. Currently, behavioral management strategies and off-label medication use are the primary approaches, so approval of AXS-05 would represent the first FDA-approved treatment specifically designed for this indication. A comparison worth considering is how these new treatment options shift the care landscape.
Previously, an Alzheimer’s diagnosis meant a progressive decline with limited medical interventions. Now, for someone diagnosed in the early symptomatic amnestic stage, there are disease-modifying treatments that can slow decline, plus emerging treatments for specific behavioral symptoms. However, access remains unequal—these newer treatments are expensive, insurance coverage is still evolving, and many patients lack access to specialized memory centers where they can be prescribed and monitored. The broader pipeline continues to advance, with multiple approaches in late-stage trials targeting different pathological mechanisms. The 2026 National Plan update will need to address how to prioritize which treatments get research funding, how to ensure equitable access, and how healthcare providers across the country can be trained to use these new tools effectively in diverse patient populations.
How the Expanded National Plan Addresses Care and Support Gaps
A significant change in the 2026 planning process is the formal inclusion of people living with dementia and their caregivers in the Advisory Council. Previous plans were developed by researchers, clinicians, and administrators, which meant that important gaps in the care system sometimes went unaddressed. By incorporating the voices of those directly affected, the 2026 plan is more likely to identify practical barriers to accessing new treatments and support services.
The NAPA Reauthorization Act expanded council membership to include representatives from additional federal agencies beyond HHS, recognizing that Alzheimer’s affects many areas of federal concern—Medicare and Medicaid financing, VA services for veterans with dementia, workforce development for caregivers, and even housing policy. This broader coordination is essential because advances in treatment mean little if patients cannot afford them, if healthcare providers aren’t trained in their use, or if caregiver support systems collapse under the burden of care. One important limitation is that a National Plan, while establishing priorities and providing framework, does not automatically fund new services or guarantee access to treatments. The 2026 plan will need to identify specific resource gaps and make the case to Congress and the administration for increased funding if it recommends new initiatives in caregiver support, dementia-competent workforce development, or equity initiatives.
Understanding the Implementation Timeline and Real-World Access
The timeline for these changes varies significantly. Some, like the May 2026 FDA decision on Leqembi starter doses, could happen within weeks. Others, like the rollout of the completed National Plan and its implementation across the healthcare system, will take months to years.
The April 30, 2026 PDUFA date for AXS-05 means that if approved, this agitation treatment could enter the market in the middle of the 2026 planning process, requiring rapid integration into the emerging plan. A practical example of the implementation challenge: even though disease-modifying Alzheimer’s treatments now exist, many primary care physicians and geriatricians lack training in identifying early-stage disease, screening for amyloid pathology, or managing the monitoring requirements of these treatments. The 2026 National Plan will need to address workforce development and training to ensure that the expanding pipeline of treatments can actually reach the patients who need them, rather than remaining concentrated at specialized memory centers in major medical centers.
What This Means for Alzheimer’s Care in the Coming Years
The 2026 National Plan update signals a fundamental shift in how the nation approaches Alzheimer’s disease—from a focus primarily on research, caregiving support, and symptom management to a model that includes disease modification and treatment diversity. With 138 drugs in clinical trials and new approvals expected throughout 2026 and beyond, the field is moving toward a reality where Alzheimer’s disease is a manageable condition rather than an invariably progressive fatal disease.
Looking forward, the success of the 2026-2035 plan will be measured not just by research advances but by equitable access, healthcare system readiness, and meaningful improvements in outcomes for diverse populations. The expansion of the planning process to include people with lived experience of dementia suggests the government recognizes that good plans require input from those most affected. The completion of the 2026 National Plan in late 2026 will provide the framework, but the real work—implementation, funding, training, and equity work—will extend throughout the 2026-2035 timeframe.
Conclusion
The 2026 update to the National Plan to Address Alzheimer’s Disease reflects dramatic changes in the treatment landscape since the previous planning cycle. The approval of disease-modifying monoclonal antibodies like Leqembi and the expanding pipeline of 138 drugs in clinical trials have transformed Alzheimer’s from a disease with no disease-modifying treatments to one with multiple therapeutic options.
The May 2026 FDA decision on Leqembi’s at-home injection form and the April 30, 2026 decision on AXS-05 for agitation will likely provide important catalysts for plan priorities. The updated National Plan, scheduled for completion in late 2026, will guide federal coordination through 2035 with an expanded framework that includes people with dementia in the planning process, broader federal agency coordination under the NAPA Reauthorization Act, and strategic alignment with emerging clinical evidence. For individuals and families affected by Alzheimer’s disease, this means staying informed about new treatment options, discussing eligibility for clinical trials or newly approved therapies with healthcare providers, and advocating for equitable access to treatments and care support in your community.
You Might Also Like
- Why the First Sign of Dementia Is Often Not Memory Loss but Changes in Mood or Personality
- Why Regular Social Meals Are Associated With Better Cognitive Health Than Eating Alone
- Why African Americans Are Twice as Likely to Develop Dementia and the Research Being Done
For more, see Alzheimer’s Association — medical tests.
